Clinical Trial

A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma

Name: A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma — clinical trial record (NCT07239986)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a Phase 2 study to evaluate the efficacy and safety of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced or unresectable FGF19-overexpressing hepatocellular carcinoma. This study has two phase: dose escalation phase and expansion phase.

Trial Details

NCT Number	NCT07239986
Lead Sponsor	Broadenbio Ltd., Co.
Conditions	Hepatocellular Carcinoma (HCC)
Enrollment	60 participants
Start Date	2025-12
Primary Completion	2027-06 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2025-11-20